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Background: Measurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for
prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment
and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in
serum of PCa patients.
Methods: Serum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without
neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins
in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing
distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa
patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability
of these molecules to detect disease and predict pathological outcome.
Results: Screening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin
warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9
under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated
negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly
correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and
better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a
Gleason Sum ≥7.
Conclusions: sE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and
predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.
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Prostate cancer (PCa) is currently the most prevalent male
neoplasia in industrialized countries, accounting for almost
12 % of cancer cases annually [1]. Besides incumbent mor-
bidity, the disease is associated with a significant economic
burden. Declining mortality is expected to cause increases
in healthcare costs as a result of increased diagnosis, diag-
nosis at an earlier stage and increased survival [2].* Correspondence: igor.tsaur@kgu.de
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unless otherwise stated.Due to the biological heterogeneity of PCa and rapidly
expanding treatment options, individualized risk-adapted
therapy incorporating patient- and tumor-specific charac-
teristics is required to optimize outcome and avoid over-
treatment with unnecessary adverse effects [3, 4]. Since
not only radical prostatectomy (RPE) or radiation, but also
active surveillance possibly postponing definite therapy,
currently represent state-of-the-art care for patients with a
localized PCa and a long life expectancy [5], identifying
cancer types with high progression risk is indispensable in
determining a treatment course. Nomograms, neural net-
works and predictive tables have all been developed in thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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PCa diagnosis and treatment [6]. Being limited in their
clinical application by problematic generalization and
population-specific issues [7], they provide an average ac-
curacy of 70 % [6]. To improve their performance, identifi-
cation of appropriate molecular biomarkers and possibly
their incorporation into predictive models is crucial [7].
Until now, prostate specific antigen (PSA) remains the
only clinically relevant diagnostic and follow-up biomarker
[8]. Recent research has been aimed at finding markers to
overcome the limits of PSA, not only to diagnose PCa but
also to distinguish between indolent and clinically signifi-
cant disease [9]. Despite initial promising reports, these
marker-candidates have fallen short following extensive val-
idation and have not proven to be of routine value.
Marker detection in serum is attractive since sampling is
simple and ideal for screening and prognostic evaluation of
PCa to facilitate treatment choices for patients with local
disease [10]. A panel of serum candidate markers known to
be involved in inflammatory processes and tumorigenesis
of different cancer types was evaluated for diagnostic and
predictive potential in a cohort of patients with PCa.Methods
Patients and controls
Study approval was granted by the local medical ethics
committee (project number SUG_01-2014). Patients
(n = 165) undergoing curative radical prostatectomy for
biopsy-proven PCa without any neoadjuvant treatment
between October 2010 and June 2014 in the Department of
Urology, Goethe-University, Frankfurt am Main, Germany,
were included in the study after having signed informed
consent to utilize biomaterial for scientific assessment. The
clinical tumor stage was classified according to the 7th edi-
tion of AJCC [11] and the pathological tumor stage was
determined according to the 6th edition of the TNM classi-
fication [12]. Tumors were graded with the Gleason Sum
(GS) [13]. Clinical and histological characteristics were col-
lected from patient charts. Risk classification was deter-
mined according to D`Amico et al. [14]. Imaging was
carried out in the high-risk group according to the guide-
lines of the European Association of Urology [15]. Epstein
criteria [16] were used to assess the clinical significance of
the tumor. Controls (n = 19) were healthy, age-matched,
male volunteers.Blood samples
10 ml peripheral blood was drawn from patients several
days before surgery and from controls. Blood samples were
allowed to coagulate and then centrifuged at 3000 rpm
at +4 °C for 10 min. The serum supernatant was stored
at -80 °C.Proteome profiler antibody array
Serum from 10 PCa patients and from 10 controls were
applied to a proteome profiler array to screen 119 markers
(Human soluble Receptor Array Kit, Non Hematopoietic
Panel, R&D systems, MN, USA) (Table 1) according to the
manufacturer’s instructions. Briefly, membranes spotted
with antibodies were blocked with Array buffer for 1 h at
room temperature on a shaker followed by incubation with
1 ml serum mixed with 3 ml of array buffer overnight at
4 °C. On the next day membranes were washed 3x with
wash buffer and further incubated with a detection anti-
body cocktail for 2 h at room temperature on a shaker.
Membranes were again washed 3x with wash buffer and
incubated with Streptavidin-HRP for 30 min at room
temperature on a shaker. Signals were visualized using the
Chemi reagent mix on a FUSION FX-7 imaging device
(Vilber Lourmat, Torcy, France).
Elisa
E-selectin, soluble (s)E-Cadherin, MMP2, MMP9, TIMP1,
TIMP2, Galectin and Clusterin, were identified as distinctly
differently expressed in the serum of PCa patients and con-
trols in the Proteome Profiler Antibody Array screening.
The concentration of these markers was determined in the
serum of 165 PCa patients and 19 controls using commer-
cially available ELISA Kits (R&DSystems, MN, USA) ac-
cording to the manufacturer’s instructions. Briefly, serum
was diluted, pipetted into wells and incubated at 37 °C or
RT for 1-2 h according to kit instructions. After incubation
plates were washed 4x, followed by incubation with detec-
tion antibodies for 30 min or 1 h at RT and wells were sub-
sequently washed 4x. TMB substrate was added to each
well for 20 min at RT, followed by the addition of stop solu-
tion. The optical density was measured spectrophotomet-
rically with an ELISA reader (Infinite M200 series, Tecan,
Crailsheim, Germany). All assays were done in duplicate
and the concentration was calculated from a standard curve
using a 4-parameter curve fit (Magellan software, Tecan).
Statistics
Univariate analysis was performed by the Wilcoxon-
Man-Whitney-test for comparison between two groups
and the Kruskal-Wallis-test with the Iman-Conover-
method (Bonferroni-Holm-corrected) for more than two
groups. Bi- and multivariate analysis was carried out by
logistic regression for two target values and multiple
regression for more than two target values. Correlation
between two parameters was evaluated through Spearman’s
coefficient. The statistical program applied was BiASfuer
Windows (Version 9.11, Dr. rer. nat. Hanns Ackermann,
epsilon-publishers, Frankfurt, Germany). The null hypoth-
esis was rejected if p-values were less than 0.05. Continuous
data were presented as median (range) or number (%), as
applicable.
Table 1 Markers screened with Proteome Profiling Antibody
A: Non-Hematopoietic Array
ADAM15 βIG-H3 BMPR-IB/ALK-6 Cadherin-4/R-Cadherin Cadherin-11
Cadherin-13 E-Cadherin N-Cadherin P-Cadherin VE-Cadherin
Cathepsin-D CD40/TNFRSF5 CEACAM-5/CD66e CHL-1/L1CAM-2 Clusterin
Coagulation-Factor II/Thrombin COMP/Thrombospondin CRELD2 Desmoglein 2 ECM-1
EGF R/ErbB1 Endoglycan EpCAM/TROP-1 ErbB2/HER2 ErbB3/HER3
ErbB4/HER4 ESAM Galectin-2 HPRG Integrin α3/CD49c
Integrin α5/CD49e Integrin α6/CD49f Integrin α9 Integrin αV/CD51 Jagged 1
JAM-B/VE-JAM JAM-C LRP-6 MCAM/CD146 MEPE
MUCDHL Nectin-2/CD112 Nectin-4 Neurotrimin Notch-1
NrCAM Periostin/OSF-2 Podocalyxin E-Selectin/CD62e Semaphorin-3A
SREC-I/SR-F1 SREC-II Stanniocalcin 1 Syndecan-1/CD138 Syndecan-4
Thrombospondin-2 TIMP-4 TROP-2 VAP-1/AOC3 VCAM-1
VEGF R1/Flt-1 VEGF R2/KDR/Flk-1
B: Common analytes array
ACE ADAM8 ADAM9 ADAM10 ALCAM/CD166
Amphiregulin APP (pan) BACE-1 BCAM C1qR1/CD93
CD9 CD23/Fc ε RII CD31/PECAM-1 CD36/SR-B3 CD40 Ligand/TNFSF5
CD44H CD58/LFA-3 CD90/Thy1 CD99 CD155/PVR
CEACAM-1/CD66a CX3CL1/Fractalkine CXCL8/IL-8 EMMPRINN/CD147 Endoglin/CD105
Epiregulin Galectin-1 Galectin-3 Galectin-3BP/MAC-2BP HB-EGF
ICAM-2/CD102 IL-1 RII IL-15 Rα Integrin β1/CD29 Integrin β2/CD18
Integrin β3/CD61 Integrin β4/CD104 Integrin β5 Integrin β6 JAM-A
Lipoclain-2/NGAL LOX-1/SR-E1 MD-1 MMP-2 (total) NCAM-1/CD56
NCAM-L1 Osteopontin PAR1 Pref-1/DLK-1/FA1 RECK
Stabilin-1 TACE/ADAM17 Thrombospondin TIMP-1 TIMP-2
TIMP-3 TNF RII/TNFRSF1B
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Clinical and pathologic demographics of 165 patients are
shown in Table 2. The median age at tumor diagnosis
was 65 years and the median serum PSA was 8.1 ng/ml.
Nearly all PCas submitted to surgery were clinically sig-
nificant. All patients were clinically free of visceral or
bone disease. None of the patients had evident clinical
signs of infection or acute or chronic inflammation at
surgery. Histologically, all tumors were conventional aci-
nar adenocarcinomas.
The screening analysis by Proteome Profiler showed
distinctly altered expression of sE-cadherin, E-selectin,
MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin in
the serum of tumor patients compared to controls. Fur-
ther ELISA investigations were based on these markers.
Univariate analysis of the ELISA investigation demon-
strated that serum sE-Cadherin, TIMP1, Galectin and
Clusterin were significantly over- and MMP9 under-
expressed in PCa patients compared to healthy controls
(all p < 0.05, Fig. 1). The concentration of sE-Cadherin,MMP2 and Clusterin correlated negatively and that of
MMP9 and TIMP1 positively with GS at prostatectomy
(all p < 0.05, Table 3), but only sE-cadherin significantly
correlated with the highest Gleason pattern (p < 0.05,
Fig. 2a). In the group of patients with a GS upgrade from
prostate biopsy to prostatectomy specimen, a decreased
concentration of sE-cadherin was observed, compared to
patients without upgrade (p < 0.05, Fig. 2b).
Multivariate analysis with logistic regression for all 8
candidate markers as well as serum PSA was unsuitable
because, taking into account the cohort size and ‘the
rule of ten’ [17], sufficient stability of the model could
not be ensured. Therefore, a bivariate logistic regression
analysis was performed, incorporating each of the candi-
date molecules and serum PSA to assess their ancillary
predictive potential over PSA for clinical and patho-
logical T-stage, L-, N-, R-, Pn-status, biopsy (b) and
prostatectomy (p)GS after dichotomization of the study
cohort into GS < 7 and ≥ 7, as well as Gleason upgrade.
Only sE-cadherin yielded favorable discriminative ability
Table 2 Clinical and histopathological demographics of 165
PCa patients
n = 165 (100 %)




Extracapsular infiltration 34 (20.6)




Serum-PSA, ng/ml 8.1 (1.8-136)
PSAD, ng/ml/ml 0.2 (0.1-1.8)
Abnormal DRE 65 (39.4)




















Clinically significant PCa (Epstein) 158 (95.8)
D’Amico Classification
Low risk 55 (33.3)
Intermediate risk 61 (37.0)






Values expressed as median with range or number (%). RPE, radical prostatectomy;
DRE, digital rectal examination, PSAD, PSA density
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(p = 0.01). Moreover, sE-cadherin better detected PCas
with a Gleason upgrade at RPE (p = 0.01) than did serum
PSA. Neither sE-cadherin, TIMP1, Galectin, Clusterin nor
MMP9 correlated significantly with serum PSA.
Discussion
Estimating PCa malignancy in an era of personalized
healthcare requires novel diagnostic and prognostic bio-
markers to develop individual treatment strategies. There-
fore, the potential of a panel of serum proteins to detect
PCa and predict histopathological outcome in curatively
treated disease was evaluated.
Out of 119 candidate molecules, sE-cadherin yielded
the most promising potential to serve as a biomarker in
the current study cohort with almost 96 % clinically
significant PCas according to the Epstein criteria [16].
E-cadherin, a type-I-cadherin, belongs to the cadherin
family of transmembrane or membrane-associated glyco-
proteins located in the adherens junction and basolateral
membrane in epithelial cells. It consists of a large extracel-
lular domain, a transmembrane segment and a conserved
cytoplasmic domain [18]. E-cadherin is indispensable in
promoting cell-cell adhesion in a Ca2+-dependant manner
and steers tissue morphogenesis [19]. During cancer pro-
gression, transcriptional E-cadherin reprogramming in-
duces decreased adhesion and enhanced migration and
invasion during the epithelial-to-mesenchymal transition
of epithelial cells [20, 21]. sE-cadherin is an 80-kDa ecto-
domain of the full-length E-cadherin, which is proteolytic-
ally shed into the extracellular space through cleavage by
secretases and caspases [18]. Concurrent to the disruption
of adhesion junctions, EGFR and Wnt/β-catenin pathway
signaling, often involved in tumorigenesis, are activated
[22]. Since E-cadherin cleavage has been linked to neo-
plastic adenoma-cancer progression, serum levels of sE-
cadherin have been shown to be augmented in patients
with breast, gastric and colorectal cancer [23]. This is in
line with our findings demonstrating that the serum con-
centration of sE-cadherin was elevated in patients with
PCa, more than other investigated candidates. Thanks to
its stability in blood, sE-cadherin may be a suitable indica-
tor for early PCa detection, due to accumulation during
tumor-associated proteolysis [23].
So far, little has been reported about sE-cadherin in
connection with PCa. Ahmed et al. [24] investigated its
potential as a biomarker in a group of 71 Egyptian males
with PCa. In agreement with our findings, significant
over-expression of sE-cadherin in the serum of tumor
patients, compared to healthy individuals, was observed.
No correlation with the clinical tumor stage was apparent.
In contrast to our findings, the authors reported high ex-
pression of sE-cadherin, correlating with a poor Gleason
grade and serum PSA. It is difficult to interpret their data
Fig. 1 Marker concentrations in serum from tumor patients and controls. Only candidate molecules with significant differences are presented.
Y-axis - concentration in ng/ml; X-axis - serum samples of tumor patients and controls. Box: lower line - quartile Q1 (25 %-quantile); middle line
- median; upper line - quartile Q3 (75 %-quantile); aerials - extreme values. * - p < 0.001 (Wilcoxon-Mann–Whitney-test). 0.05 > p ≥ 0.01 are given
in exact numbers
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size of that cohort, median PSA of 70.7 ng/ml for tumor
patients, most cancers classified as stage D and details
about their staging procedure absent. These study charac-
teristics harbor significant probability of undetected me-
tastasis and therefore deviate from the present study
population, which was clinically free from visceral- andTable 3 Correlation of markers with prostatectomy Gleason Sum
sE-Cadherin MMP2 MMP9 TIMP1 Clusterin
p-value 0.004599 0.020268 0.048087 0.027881 0.031574
Coefficient
(rho)
−0.219991 −0.180763 0.154655 0.171867 −0.168062bone-disease. Furthermore, alterations in Gleason grading
procedures over time have resulted in significant tumor
up-grading [25], making a study published in 1999 [24] dif-
ficult to compare with the present study carried out more
than a decade later, due to bias stemming from the Will
Rogers phenomenon. Later, Kuefer et al. [26] observed no
difference between the expression of serum sE-cadherin in
61 men with localized PCa compared to controls. On the
contrary, a more contemporary series also involving 61
patients with clinically localized PCa, reported by Iacopino
et al. [27], demonstrated serum sE-cadherin over-expres-
sion in PCa patients compared to that of healthy individ-
uals, which is similar to our observation. However, no
correlation of the marker with PSA, T-stage, GS, grade or
Fig. 2 Associations between sE-cadherin and histopathological parameters. a: Association between sE-cadherin expression and highest Gleason pattern.
Y-axis - concentration in ng/ml; X-axis - serum samples of tumor patients distributed by the highest Gleason pattern (hGP). G3-G5 - Gleason pattern 3-5.
P-value (Kruskal-Wallis-test). b: Association between sE-cadherin expression and Gleason sum upgrade. Y-axis - concentration in ng/ml; X-axis - serum
samples of tumor patients distributed by upgrade status of the Gleason sum in prostatectomy specimen. P-value (Wilcoxon-Mann–Whitney-test). Box:
lower line - quartile Q1 (25 %-quantile); middle line - median; upper line - quartile Q3 (75 %-quantile); aerials - extreme values
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best knowledge, the current assessment of sE-cadherin
has taken place in the largest cohort of clinically non-
metastatic males with PCa. sE-cadherin correlated with
the highest Gleason pattern, which is an important prog-
nosis factor [28] and was also associated with a Gleason
upgrade and pGS, which is more accurate than bGS at
predicting biochemical recurrence after RPE [29]. Most
importantly, for identifying more aggressive tumors with
GS ≥ 7 and tumors with a Gleason upgrade, sE-cadherin
outmatched serum PSA without correlating with this
marker.
The negative serum sE-cadherin correlation with more
aggressive PCa in this investigation requires further re-
search since serum sE-cadherin has been reported to rise
with more aggressive or advanced stages in many other
cancer types [23]. However, Juhasz et al. has provided
evidence for significantly decreased expression of serum
sE-cadherin in individuals with advanced and metasta-
sized diffuse-type gastric cancer in contrast to intestinal
cancer [30]. Careful analysis of cancer type as well asstage and grade specific molecular machinery pertaining
to E-cadherin turnover is therefore warranted. Ongoing
studies on sE-cadherin with respect to PCa should also
take into consideration that proinflammatory cytokines
[31], growth factors [32], as well as chemically induced
oxidative stress [33] may contribute to its generation
and possibly falsify results based on its expression.
Although sE-cadherin seems to be a promising bio-
marker, it may not be alone. Catenins, as well as CD44,
are associated with E-cadherin in regulating prostate can-
cer cell adhesion [34]. In particular, CD44v8–10 have been
shown to be negatively correlated with c-Myc expression,
both in vitro and in vivo. The negative correlation may
partly be attributable to redox stress-enhanced Wnt/beta-
catenin signaling [35].
The reason no distinct difference was apparent between
the CD44 serum level in healthy subjects and tumor pa-
tients may have been because CD44 variants such as
CD44v5, CD44v6 and CD44v10, possibly involved in pros-
tate cancer progression, were not individually evaluated
[36,37]. EpCAM differences between tumor patients and
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tion, which is in line with other reports [38]. EpCAM has
been reported to be responsible for persistence of minimal
residual disease and latent relapse of prostate cancer, pre-
sumably by affecting the susceptibility to the EGF ligand
and regulating the AMPK signaling pathway [39]. Never-
theless, a prognostic/diagnostic role of EpCAM in EGFR
activated prostate cancer cells should not be ruled out.
The same ambivalence might apply to MMP9. Although
this protein has been suggested to correlate with prostate
cancer progression, the correlation has not always been
substantiated. Recent experiments documented that MMP9
might even exert tumor-suppressive properties. In fact,
elevated MMP9 secretion has been shown to result in
decreased prostate cancer cell proliferation, coupled to
increased sE-cadherin shedding [40]. The combined effect
might explain the inverse correlation between sE-cadherin
and MMP9 found in the present investigation, whereby
reduced MMP9 and elevated sE-cadherin may drive tumor
proliferation forward. Still, this is hypothetical and requires
further evaluation.
The present investigation is limited by its single-center de-
sign and lack of external validation. To account for regional
and racial disparity regarding the biological characteristics of
PCa [41], validation studies with patient cohorts from other
centers would be desirable. The potential of sE-cadherin as
a biomarker could thereby be more exactly appraised.
Conclusions
To sum up, sE-cadherin performed best out of a large panel
of serum proteins in terms of diagnostic and predictive po-
tential in 165 patients with clinically localized PCa.
Therefore, this molecule merits further investigation as a
biomarker for PCa.
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